What is myelofibrosis?

Myelofibrosis is a chronic hematologic disorder characterized by replacement of normal bone marrow hematopoietic tissue with fibrous connective tissue, leading to progressive impairment of hematopoiesis. This results in abnormal blood cell counts, splenomegaly, and persistent fatigue, among other symptoms. Disease progression varies significantly among individuals and requires long-term monitoring and management. Frequent fatigue, abdominal distension, and unintentional weight loss warrant prompt medical evaluation and diagnostic workup.

Myelofibrosis originates from pathological changes in the bone marrow hematopoietic microenvironment, triggering abnormal proliferation of fibrous tissue. This encroaches upon the space required for normal hematopoietic cells, progressively diminishing the bone marrow’s capacity to produce blood cells. Patients commonly develop anemia and dysregulated white blood cell and platelet counts, accompanied by compensatory splenomegaly. Clinically, treatment strategies—including pharmacotherapy—are tailored to disease severity to modulate hematopoiesis, slow fibrotic progression, and stabilize key physiological parameters.

As the disease advances, it progressively depletes systemic functional reserves, manifesting as weight loss, night sweats, and bone or joint aches. In severe cases, hematopoietic function may fail completely. At advanced stages, targeted therapies and allogeneic hematopoietic stem cell transplantation may be employed to correct hematopoietic abnormalities, delay disease progression, improve physiological tolerance, and preserve essential organ function.

In daily life, maintaining regular sleep-wake cycles and consuming a light, nutritionally balanced diet is recommended. Patients should avoid excessive physical exertion, infections, and other adverse triggers; manage emotional stress effectively; and ensure consistent rest and recuperation to reinforce baseline physiological stability and minimize functional deterioration.